A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Eli Lilly and Company
Pfizer
UMC Utrecht
Pfizer
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
Natera, Inc.
Novartis
Var2 Pharmaceuticals
City of Hope Medical Center
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
Washington University School of Medicine
A2 Biotherapeutics Inc.
Elicio Therapeutics
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Shanghai Cingularbio Co. Ltd
Columbia University
University of Arizona
Tempus AI
Instituto de Investigacion Sanitaria La Fe
Stanford University
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
Taproot Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chongqing Precision Biotech Co., Ltd
UTC Therapeutics Inc.
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Qianfoshan Hospital